Skip to Content

New Drug Approvals Archive - July 2007

July 2007

Atralin (tretinoin) Gel

Date of Approval: July 26, 2007
Company: Coria Laboratories, Ltd.
Treatment for: Acne

Atralin (tretinoin) gel is a retinoid indicated for topical treatment of acne vulgaris.

Read more: Atralin (tretinoin) FDA Approval History

Privigen (immune globulin intravenous (human)) Liquid

Date of Approval: July 26, 2007
Company: CSL Behring
Treatment for: Primary Immunodeficiency Syndrome, Idiopathic (Immune) Thrombocytopenic Purpura, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency (PI), chronic immune thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).

Read more: Privigen (immune globulin intravenous (human)) FDA Approval History

CaloMist (cyanocobalamin) Nasal Spray

Date of Approval: July 27, 2007
Company: Fleming & Company, Pharmaceuticals
Treatment for: Vitamin B12 Deficiency

CaloMist is a nasal spray formulation of cyanocobalamin indicated for the maintenance of vitamin B12 concentrations in patients with vitamin B12 deficiency who have been normalized with intramuscular vitamin B12 therapy.

Read more: CaloMist (cyanocobalamin) FDA Approval History

EvaMist (estradiol) Transdermal Spray

Date of Approval: July 27, 2007
Company: VIVUS, Inc.
Treatment for: Postmenopausal Symptoms

EvaMist is an estradiol transdermal spray administered once daily for the treatment of vasomotor symptoms (hot flashes) associated with menopause.

Read more: EvaMist (estradiol) FDA Approval History

New Drug Approvals Archive